Eintrag weiter verarbeiten
Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected ade...
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Journal of Clinical Oncology, 29, 2011, 4_suppl, S. 435-435 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Conradi, L. Bleckmann, A. Schirmer, M. Sprenger, T. Homayounfar, K. Wolff, H. A. Becker, H. Ghadimi, B. M. Beissbarth, T. Liersch, T. Conradi, L. Bleckmann, A. Schirmer, M. Sprenger, T. Homayounfar, K. Wolff, H. A. Becker, H. Ghadimi, B. M. Beissbarth, T. Liersch, T. |
|---|---|
| author |
Conradi, L. Bleckmann, A. Schirmer, M. Sprenger, T. Homayounfar, K. Wolff, H. A. Becker, H. Ghadimi, B. M. Beissbarth, T. Liersch, T. |
| spellingShingle |
Conradi, L. Bleckmann, A. Schirmer, M. Sprenger, T. Homayounfar, K. Wolff, H. A. Becker, H. Ghadimi, B. M. Beissbarth, T. Liersch, T. Journal of Clinical Oncology Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. Cancer Research Oncology |
| author_sort |
conradi, l. |
| spelling |
Conradi, L. Bleckmann, A. Schirmer, M. Sprenger, T. Homayounfar, K. Wolff, H. A. Becker, H. Ghadimi, B. M. Beissbarth, T. Liersch, T. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2011.29.4_suppl.435 <jats:p> 435 </jats:p><jats:p> Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). </jats:p><jats:p> Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. </jats:p><jats:p> Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of *3/*3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). </jats:p><jats:p> Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2011.29.4_suppl.435 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS4yOS40X3N1cHBsLjQzNQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS4yOS40X3N1cHBsLjQzNQ |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2011 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2011 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
conradi2011biomarkerstudyinrectalcancerpatientsafter5fubasedradiochemotherapyevaluationoftheprognosticcapacityofthymidylatesynthaseinpretreatmentbiopsiesandresectedadenocarcinoma |
| publishDateSort |
2011 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_unstemmed |
Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_full |
Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_fullStr |
Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_full_unstemmed |
Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_short |
Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_sort |
biomarker study in rectal cancer patients after 5fu-based radiochemotherapy: evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2011.29.4_suppl.435 |
| publishDate |
2011 |
| physical |
435-435 |
| description |
<jats:p> 435 </jats:p><jats:p> Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). </jats:p><jats:p> Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. </jats:p><jats:p> Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of *3/*3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). </jats:p><jats:p> Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> |
| container_issue |
4_suppl |
| container_start_page |
435 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
29 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792327936736493569 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:45:19.54Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Biomarker+study+in+rectal+cancer+patients+after+5FU-based+radiochemotherapy%3A+Evaluation+of+the+prognostic+capacity+of+thymidylate+synthase+in+pretreatment+biopsies+and+resected+adenocarcinoma.&rft.date=2011-02-01&genre=article&issn=1527-7755&volume=29&issue=4_suppl&spage=435&epage=435&pages=435-435&jtitle=Journal+of+Clinical+Oncology&atitle=Biomarker+study+in+rectal+cancer+patients+after+5FU-based+radiochemotherapy%3A+Evaluation+of+the+prognostic+capacity+of+thymidylate+synthase+in+pretreatment+biopsies+and+resected+adenocarcinoma.&aulast=Liersch&aufirst=T.&rft_id=info%3Adoi%2F10.1200%2Fjco.2011.29.4_suppl.435&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792327936736493569 |
| author | Conradi, L., Bleckmann, A., Schirmer, M., Sprenger, T., Homayounfar, K., Wolff, H. A., Becker, H., Ghadimi, B. M., Beissbarth, T., Liersch, T. |
| author_facet | Conradi, L., Bleckmann, A., Schirmer, M., Sprenger, T., Homayounfar, K., Wolff, H. A., Becker, H., Ghadimi, B. M., Beissbarth, T., Liersch, T., Conradi, L., Bleckmann, A., Schirmer, M., Sprenger, T., Homayounfar, K., Wolff, H. A., Becker, H., Ghadimi, B. M., Beissbarth, T., Liersch, T. |
| author_sort | conradi, l. |
| container_issue | 4_suppl |
| container_start_page | 435 |
| container_title | Journal of Clinical Oncology |
| container_volume | 29 |
| description | <jats:p> 435 </jats:p><jats:p> Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). </jats:p><jats:p> Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. </jats:p><jats:p> Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of *3/*3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). </jats:p><jats:p> Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> |
| doi_str_mv | 10.1200/jco.2011.29.4_suppl.435 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMS4yOS40X3N1cHBsLjQzNQ |
| imprint | American Society of Clinical Oncology (ASCO), 2011 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2011 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:45:19.54Z |
| match_str | conradi2011biomarkerstudyinrectalcancerpatientsafter5fubasedradiochemotherapyevaluationoftheprognosticcapacityofthymidylatesynthaseinpretreatmentbiopsiesandresectedadenocarcinoma |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 435-435 |
| publishDate | 2011 |
| publishDateSort | 2011 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Conradi, L. Bleckmann, A. Schirmer, M. Sprenger, T. Homayounfar, K. Wolff, H. A. Becker, H. Ghadimi, B. M. Beissbarth, T. Liersch, T. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2011.29.4_suppl.435 <jats:p> 435 </jats:p><jats:p> Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). </jats:p><jats:p> Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. </jats:p><jats:p> Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of *3/*3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). </jats:p><jats:p> Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. Journal of Clinical Oncology |
| spellingShingle | Conradi, L., Bleckmann, A., Schirmer, M., Sprenger, T., Homayounfar, K., Wolff, H. A., Becker, H., Ghadimi, B. M., Beissbarth, T., Liersch, T., Journal of Clinical Oncology, Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma., Cancer Research, Oncology |
| title | Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_full | Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_fullStr | Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_full_unstemmed | Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_short | Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_sort | biomarker study in rectal cancer patients after 5fu-based radiochemotherapy: evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| title_unstemmed | Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2011.29.4_suppl.435 |